Advanced

Venous thrombosis in children and adolescents with Hodgkin lymphoma in Sweden

Schönning, A.; Karlén, J.; Frisk, T; Heyman, M M; Svahn, J. E. LU ; Øra, I. LU ; Kawan, L.; Holmqvist, B. M.; Björklund, C. and Harila-Saari, Arja, et al. (2017) In Thrombosis Research 152. p.64-68
Abstract

Introduction Pediatric patients with Hodgkin lymphoma (HL) have several risk factors for venous thromboembolism (VTE). Although these patients are occasionally treated with thromboprophylaxis, no guidelines are implemented in Sweden. Scarce data from adult patients indicate an increased risk of VTE, but pediatric data is largely missing. Given the favorable overall survival of HL, there should reasonably be more focus on preventing complications. Materials and methods We conducted a retrospective cohort study, including all patients registered in the Childhood Cancer Registry under the age of 18 years diagnosed with HL between January 2005 and December 2015 in Sweden. Results Data was retrieved from the medical records of all 163... (More)

Introduction Pediatric patients with Hodgkin lymphoma (HL) have several risk factors for venous thromboembolism (VTE). Although these patients are occasionally treated with thromboprophylaxis, no guidelines are implemented in Sweden. Scarce data from adult patients indicate an increased risk of VTE, but pediatric data is largely missing. Given the favorable overall survival of HL, there should reasonably be more focus on preventing complications. Materials and methods We conducted a retrospective cohort study, including all patients registered in the Childhood Cancer Registry under the age of 18 years diagnosed with HL between January 2005 and December 2015 in Sweden. Results Data was retrieved from the medical records of all 163 patients (100%) at six Swedish pediatric cancer centers. The incidence of VTE was 7.7% (symptomatic VTE 3.9%). The median follow-up was 3.4 years (range 0.3–10.5). Only five patients (3.1%) were treated with thromboprophylaxis. All VTE events occurred in the older age category (11–17 years) and all but one (92.7%) had a mediastinal mass. While the VTE did not significantly affect the treatment of HL, it caused increased morbidity and 2/12 developed a post-thrombotic syndrome. No significant risk factors for VTE were identified. Conclusions VTE is a relatively common complication of HL and its treatment, causing increased acute and long-term morbidity. However, due to limited number of events we could not demonstrate risk-factors for VTE that would identify patients who might benefit from thromboprophylaxis.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adolescents, Children, Hodgkin lymphoma, Venous thromboembolism
in
Thrombosis Research
volume
152
pages
5 pages
publisher
Elsevier Ltd
external identifiers
  • scopus:85013821421
  • wos:000399245600013
ISSN
0049-3848
DOI
10.1016/j.thromres.2017.02.011
language
English
LU publication?
yes
id
2578ad64-f227-4a12-a402-a80ea3c754f5
date added to LUP
2017-03-09 12:17:21
date last changed
2018-01-07 11:54:47
@article{2578ad64-f227-4a12-a402-a80ea3c754f5,
  abstract     = {<p>Introduction Pediatric patients with Hodgkin lymphoma (HL) have several risk factors for venous thromboembolism (VTE). Although these patients are occasionally treated with thromboprophylaxis, no guidelines are implemented in Sweden. Scarce data from adult patients indicate an increased risk of VTE, but pediatric data is largely missing. Given the favorable overall survival of HL, there should reasonably be more focus on preventing complications. Materials and methods We conducted a retrospective cohort study, including all patients registered in the Childhood Cancer Registry under the age of 18 years diagnosed with HL between January 2005 and December 2015 in Sweden. Results Data was retrieved from the medical records of all 163 patients (100%) at six Swedish pediatric cancer centers. The incidence of VTE was 7.7% (symptomatic VTE 3.9%). The median follow-up was 3.4 years (range 0.3–10.5). Only five patients (3.1%) were treated with thromboprophylaxis. All VTE events occurred in the older age category (11–17 years) and all but one (92.7%) had a mediastinal mass. While the VTE did not significantly affect the treatment of HL, it caused increased morbidity and 2/12 developed a post-thrombotic syndrome. No significant risk factors for VTE were identified. Conclusions VTE is a relatively common complication of HL and its treatment, causing increased acute and long-term morbidity. However, due to limited number of events we could not demonstrate risk-factors for VTE that would identify patients who might benefit from thromboprophylaxis.</p>},
  author       = {Schönning, A. and Karlén, J. and Frisk, T and Heyman, M M and Svahn, J. E. and Øra, I. and Kawan, L. and Holmqvist, B. M. and Björklund, C. and Harila-Saari, Arja and Ranta, S},
  issn         = {0049-3848},
  keyword      = {Adolescents,Children,Hodgkin lymphoma,Venous thromboembolism},
  language     = {eng},
  month        = {04},
  pages        = {64--68},
  publisher    = {Elsevier Ltd},
  series       = {Thrombosis Research},
  title        = {Venous thrombosis in children and adolescents with Hodgkin lymphoma in Sweden},
  url          = {http://dx.doi.org/10.1016/j.thromres.2017.02.011},
  volume       = {152},
  year         = {2017},
}